MedTrace Logo

Clinical Study of Combined Platelet Transfusion

NCT06613425 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-09-26

No results posted yet for this study

Summary

Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.

Conditions

Interventions

COMBINATION_PRODUCT

Combined platelets

1 therapeutic dose combined platelet contained no less than 2.5 ×10\^11 platelets as a quality standard.

Sponsors & Collaborators

  • The General Hospital of Western Theater Command

    lead OTHER

Principal Investigators

  • zhang li · The General Hospital of Weastern Theater Command

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-07-29
Completion
2025-10-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613425 on ClinicalTrials.gov